TICKERNERD
Menu
SGMTSGMTHealthcare · Biotechnology

SGMT Stock Forecast: Sagimet Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
−1.72% on the day

The 10 Wall Street analysts covering Sagimet Biosciences, Inc. hold a median 12-month price target of $29 — +162.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 10 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$687.5M
Ticker Nerd rank
35 / 100
Median analyst target
$29
Analysts covering
10
Revenue$0.0
Operating income−$15.8M
Net income−$14.0M
Free cash flow−$11.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
+14.2%
YTD
+83.6%
1Y
+54.4%
From 52W high
−1.7%
From 52W low
+138.9%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sagimet Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
75
Growth
72
Value
55
Quality
52
Size
50
Revisions
40
Accruals
22
Volatility
21
Issuance
17

Momentum (75): The shares have been drifting up relative to others.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26SGMTHigh $56Median $29Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $8Median $29High $56

The green dot is the last close — the median target sits +162.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$29
14 Aug 2026CitizensMaintainsMarket Outperform—
14 Aug 2026CitizensMaintainsMarket Outperform$12 → $29
12 Aug 2026Canaccord GenuityMaintainsBuy—
12 Aug 2026Canaccord GenuityMaintainsBuy$49 → $56
19 May 2026CitizensMaintainsMarket Outperform$35 → $12
19 May 2026CitizensMaintainsMarket Outperform—
4 May 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026GuggenheimMaintainsBuy—
11 Mar 2026HC Wainwright & Co.ReiteratesBuy—
3 Feb 2026GuggenheimInitiatesBuy—
3 Feb 2026HC Wainwright & Co.ReiteratesBuy—
28 Jan 2026BarclaysInitiatesEqual-Weight—
14 Nov 2025CitizensMaintainsMarket Outperform—
22 Oct 2025Clear StreetInitiatesBuy—
2 Oct 2025Canaccord GenuityMaintainsBuy—
11 Aug 2025WedbushInitiatesOutperform—
7 Aug 2025HC Wainwright & Co.AssumesBuy$29
24 July 2025Canaccord GenuityInitiatesBuy—
6 June 2025Jones TradingMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SGMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Sagimet Biosciences, Inc. returned +54.4% against +17.5% for the S&P 500, dividends included.

SGMT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26SGMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
3
Fundamentals

Sagimet Biosciences, Inc. (SGMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.0×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
2.7×

Cheaper than 36% of US stocks

EV / EBITDA
−7.9×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−24.4%

Higher than 29% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sagimet Biosciences, Inc. (SGMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sagimet Biosciences, Inc. has a market value of $687.5M and an enterprise value of $449.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$47.1M.

  • Diluted earnings per share, trailing twelve months: $−1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$41.7M.

  • Shares outstanding: 61.8M.

  • Trailing P/E: −7.0×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sagimet Biosciences, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

SGMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGMTSagimet Biosciences, Inc.$687.5M
35
MDXGMiMedx Group, Inc.$683.4M
75
VSTMVerastem, Inc.$669.3M
60
BLSMBlossomhill Therapeutics, Inc.$659.1M
1
NGNENeurogene, Inc.$697.2M
60
PHATPhathom Pharmaceuticals, Inc.$655.3M
73
ZVRAZevra Therapeutics, Inc.$708.1M
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sagimet Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGMT news & analysis

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Sagimet Biosciences announced that management will participate in two upcoming investor conferences. The clinical-stage biopharmaceutical company focused on metabolic and fibrotic pathways made the disclosure in a Sept. 2 press release.

Why it matters — SGMT watchers would care because investor conference participation offers management a platform to present the company's pipeline and progress to the investment community.

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

GlobeNewsWire · 25 Aug 2026positive

Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat in moderate to severe acne is on track to begin enrollment in Q4 2026. All clinical trial sites have been identified, a CRO has been retained, and patient screening is expected to begin in October 2026.

Why it matters — The announcement confirms the timely advancement of Sagimet's Phase 3 acne trial, keeping the denifanstat program on schedule for a key clinical milestone in late 2026.

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Aug 2026neutral

Sagimet Biosciences announced that its Compensation Committee approved an inducement grant of 260,700 stock options in aggregate to purchase shares of Series A common stock, granted on August 17, 2026, to three newly hired employees in connection with their hiring, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — SGMT watchers would care because this equity grant reflects new employee hiring and stock-based compensation, a routine corporate governance disclosure relevant to share dilution and the company's hiring activity.

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

MarketBeat · 17 Aug 2026positive

Sagimet Biosciences announced plans to initiate a U.S. Phase III study of its oral FASN inhibitor denifanstat for moderate-to-severe acne within the coming months, after its partner Ascletis reported positive results from a China-based Phase III trial. The disclosure was made by company executives during a Canaccord Genuity discussion.

Why it matters — The positive China Phase III results and planned U.S. Phase III study signal continued advancement of Sagimet's denifanstat pipeline into a new, potentially significant indication for acne.

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

GlobeNewsWire · 13 Aug 2026positive

Sagimet Biosciences announced it received an FDA "Study May Proceed" letter and IND clearance for a Phase 3 clinical trial of denifanstat in moderate to severe acne in adolescent and adult patients in the U.S. The trial is on track to initiate in the second half of 2026.

Why it matters — This regulatory clearance advances Sagimet's acne program toward a Phase 3 trial, a key clinical milestone for the company's pipeline.

FAQ

Frequently asked questions about SGMT stock

What is the SGMT stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Sagimet Biosciences, Inc. have a median 12-month price target of $29, with estimates ranging from $8 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGMT stock a buy right now?

Of the 10 analysts covering Sagimet Biosciences, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sagimet Biosciences, Inc. 35 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGMT?

As at 10 Sept 2026, Sagimet Biosciences, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (75 of 100).

Will SGMT stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +162.2% from the last close, and Ticker Nerd's factor model ranks Sagimet Biosciences, Inc. 35 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGMT stock forecast for 2030?

No analyst covering Sagimet Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $56 over the next 12 months.

How has SGMT stock performed over the past year?

Sagimet Biosciences, Inc. returned +54.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sagimet Biosciences, Inc. do?

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases.

What is the latest news on SGMT?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences". Sagimet Biosciences announced that management will participate in two upcoming investor conferences. The clinical-stage biopharmaceutical company focused on metabolic and fibrotic pathways made the disclosure in a Sept. 2 press release.

Company

About Sagimet Biosciences, Inc.

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.

CEO Mr. David A. Happel · 16 employees · United States · https://www.sagimet.com